Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 52.41M | 54.03M | 48.80M | 54.34M | 34.05M | 15.89M |
Gross Profit | 12.70M | 8.45M | 9.85M | 9.16M | 6.33M | 10.47M |
EBITDA | 1.06M | -6.14M | -2.79M | -16.76M | 6.24M | -7.04M |
Net Income | -1.97M | -10.59M | -9.50M | -188.89M | -17.76M | -28.70M |
Balance Sheet | ||||||
Total Assets | 41.07M | 39.19M | 48.81M | 60.68M | 287.39M | 38.12M |
Cash, Cash Equivalents and Short-Term Investments | 794.00K | 863.00K | 1.81M | 2.45M | 13.90M | 8.88M |
Total Debt | 15.65M | 18.01M | 13.78M | 11.53M | 29.27M | 990.00K |
Total Liabilities | 37.01M | 36.04M | 35.11M | 36.88M | 82.44M | 25.51M |
Stockholders Equity | 3.52M | 5.24M | 14.47M | 22.65M | 201.24M | 11.10M |
Cash Flow | ||||||
Free Cash Flow | 2.44M | -1.23M | -8.66M | -14.20M | -38.97M | -10.63M |
Operating Cash Flow | 2.54M | -1.08M | -8.07M | -12.64M | -34.37M | -7.92M |
Investing Cash Flow | -53.00K | -470.00K | -1.18M | -1.41M | -9.01M | -4.08M |
Financing Cash Flow | 355.00K | 3.83M | 9.42M | 4.76M | 48.73M | 6.74M |
On August 4, 2025, IM Cannabis Corp. announced that it will release its second quarter 2025 financial results on August 12, 2025. The company, which operates in Israel and Germany, continues to focus on strengthening its position in the medical cannabis market. This announcement is significant as it highlights the company’s ongoing efforts to maintain transparency with stakeholders and its commitment to growth in key markets.
On July 30, 2025, IM Cannabis Corp completed a private placement offering, raising approximately C$5.6 million through the sale of 2,050,000 units at C$2.74 per unit. Each unit includes one common share or a pre-funded warrant and a purchase warrant, with the proceeds intended for working capital and debt repayment. Additionally, on July 31, 2025, IM Cannabis entered into a consulting agreement with Pure Equity Ltd., issuing a warrant for 140,000 shares and a cash payment of $260,000 for consulting services related to the offering. This move is expected to bolster the company’s financial position and operational capabilities.
On July 11, 2025, IM Cannabis Corp. announced the filing and effectiveness of a shelf registration statement on Form F-3 with the SEC. This registration allows the company to offer and sell up to $50 million of its securities, including common shares and warrants, subject to market conditions and capital needs. The announcement signifies IM Cannabis Corp.’s strategic move to potentially access capital markets and raise future financing, which could impact its operations and industry positioning.
On July 1, 2025, IM Cannabis Corp. announced that it received a deficiency letter from Nasdaq on April 9, 2025, for not meeting the minimum stockholders’ equity requirement for continued listing. The company submitted a compliance plan on May 23, 2025, and was granted an extension until October 6, 2025, to meet the requirements. Failure to comply by the deadline may result in delisting, although the company’s shares will continue trading under the symbol ‘IMCC’. IM Cannabis is committed to taking all reasonable measures to regain compliance, but there is no assurance of success.